Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Analytikerkommentar

Another welfare services country is piloting Nightingale's technology

Nightingale Health

Oversigt

  • Nightingale Health announced a pilot project with North Karelia wellbeing services county to integrate its blood analysis technology into health check-ups for unemployed individuals, aiming for a cost-effective preventive healthcare model.
  • This initiative marks Nightingale's second collaboration with Finnish public healthcare, following a similar project with South Savo, indicating growing public sector interest despite no immediate financial impact.
  • The pilot, set to begin testing in the first half of 2026, targets statutory health check-ups, aligning with Nightingale's strategy to integrate into existing healthcare processes without major changes.
  • The project's success could enhance Nightingale's reference value, potentially leading to broader adoption in North Karelia or other counties, although its short-term financial impact is expected to be minor.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 12/18/2025 at 8:10 pm EET.

Nightingale Health announced on Thursday that the North Karelia wellbeing services county is piloting the company's blood analysis technology as part of health check-ups for unemployed individuals. The project aims to develop a cost-effective and impactful operating model for preventive healthcare. The project will start immediately with preliminary preparations, and the actual testing is scheduled to begin in the first half of 2026. The news is a positive signal of the company's technology being of interest to the public sector, but due to its pilot nature, it has no immediate impact on our forecasts.

A step towards broader public sector adoption

The project now announced is Nightingale's second opening in Finnish public healthcare, as the company has previously reported similar cooperation with the South Savo wellbeing services county. We consider the public sector a significant but slowly developing potential market for Nightingale. The new pilot project is an encouraging sign of the interest Nightingale's technology has generated in welfare areas struggling with cost pressures. We originally commented on the company's public sector initiative here in June.

The target group selected for the North Karelia wellbeing services county pilot, health check-ups for unemployed individuals, is a statutory service. This provides a natural and existing process for piloting new technology without massive changes to treatment pathways. This is in line with Nightingale's strategy, which aims to integrate into existing healthcare routines and value chains.

The project will proceed to the testing phase in the first half of 2026, and its financial impact is, in our view, minor in the short term. However, the success of the pilot is important for its reference value, as it could open doors for wider use in North Karelia or other wellbeing services counties in the future. We will be following with interest how the pilot progresses and whether Nightingale can demonstrate concrete benefits that would lead to a permanent and broader commercial agreement.

 

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Læs mere på virksomhedsside

Key Estimate Figures19.09.2025

202526e27e
Omsætning4,77,98,8
vækst-%7,7 %67,2 %12,1 %
EBIT (adj.)-19,4-17,3-15,2
EBIT-% (adj.)-413,7 %-220,4 %-172,8 %
EPS (adj.)-0,30-0,27-0,24
Udbytte0,000,000,00
Udbytte %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forumopdateringer

Pathology Asia/Innoquest-helheden ville helt sikkert have været interessant, men den blev valgt fra på spørgsmålslisten denne gang på grund ...
2.1.2026, 07.04
af Antti Luiro
5
@Antti_Luiro tak for interviewet. Rigtig fint med sådan et ekstraafsnit. Jeg lyttede opmærksomt igen, og det begyndte at lyde lidt bedre end...
31.12.2025, 08.04
af Cle
5
Forhåbentlig vil den medicinske direktør, som de søger efter nu, kommunikere om disse kliniske applikationer i den nærmeste fremtid, og ikke...
23.12.2025, 17.21
af omegaalpha
0
Jeg klamrer mig til dette numeriske ”ti pilotcases i løbet af foråret” samt målet om 50 % omsætningsvækst som en druknende til et halmstrå, ...
23.12.2025, 15.19
af Cle
2
Tak for interviewet. Det skrider altså fremad, men det er godt nok et langt sejt træk, præcis som det er blevet kommunikeret. Nu er målet for...
23.12.2025, 06.40
af Puutaheinää
8
Jeg har spurgt Teemu om nyt fra efteråret og den tidlige vinter i denne video glædelig jul til tråden! Inderes Nightingale Health: Kaupalliset...
22.12.2025, 19.53
af Antti Luiro
19
@Homeros Denne Nature-artikel fra 2022 er ikke skrevet af personer ansat hos NG. Der var tale om Nature-artiklen fra 2023. Desuden glemmes det...
20.12.2025, 16.25
af Monsieur
3
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.